Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy?: Figure 1–
Year: 2012
Type: editorial
Abstract: diopathic pulmonary fibrosis (IPF) is a distinct clinical entity that generally affects people who are over 60 yrs of age, and median survival ranges from 3 to 5 yrs after the diagnosis is ascertained. The natural course of IPF is well known: the majority of patients with IPF display steady decline in lung function, some patients remain stable for prolonged periods of time, a subgroup of patients rapidly decline, and a subset of patients manifest acute exacerbations of IPF preceding death [1]. While several key cellular and molecular events that are thought to follow ‘‘injury’ ’ have been identified in the pathogenesis of IPF [2], the ultimate cause of IPF and the triggering factor(s) that injure the lung remain elusive, and none of the currently available pharmacological agents have demonstrated improved outcomes and survival in patients with IPF. The incidence and prevalence of IPF is highly linked to advanced
Source: European Respiratory Journal
Authors: G. Raghu, K.C. Meyer
Institution: University of Washington
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2105872263
